GRK5 and triple-negative breast carcinoma: Sunitinib, a kinase inhibitor, was found to inhibit downstream CDC42 and RHO kinases 1 (ROCK1) functions by targeting G Protein-Coupled Receptor Kinase 5 (GRK5) to modulate the motility of triple-negative breast cancer cells [161].